(Total Views: 97)
Posted On: 07/02/2024 7:57:18 AM
Post# of 36258
$VTAK Catheter Precision, Inc. (NYSE American:VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024
https://www.accesswire.com/883834/catheter-pr...ne-30-2024
15% Quarter Over Quarter Growth - Initial Sales of LockeT Recorded
FORT MILL, SC / ACCESSWIRE / July 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Revenue for the quarter ending June 30, 2024.
Catheter Precision, Inc. recognized its first sales of LockeT in the quarter ending June 30, 2024 resulting in revenue of $40,500. An additional $54,340 of revenue was recognized in the quarter ending June 30, 2024 for sale of VIVO products. Total revenue for the quarter and six months ended June 30, 2024 was $94,840 and $176,923, respectively.
"We are pleased to announce these preliminary unaudited revenues", said David Jenkins, CEO and Executive Chairman of Catheter Precision. "The very initial results of the onboarding of our new sales team, completed with the hire of Marie Claude Jaques as our new Chief Commercial Officer during May, are showing promise. The pipeline of potential customers is established and growing, giving us good insight for future revenue growth."
https://www.accesswire.com/883834/catheter-pr...ne-30-2024
15% Quarter Over Quarter Growth - Initial Sales of LockeT Recorded
FORT MILL, SC / ACCESSWIRE / July 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Revenue for the quarter ending June 30, 2024.
Catheter Precision, Inc. recognized its first sales of LockeT in the quarter ending June 30, 2024 resulting in revenue of $40,500. An additional $54,340 of revenue was recognized in the quarter ending June 30, 2024 for sale of VIVO products. Total revenue for the quarter and six months ended June 30, 2024 was $94,840 and $176,923, respectively.
"We are pleased to announce these preliminary unaudited revenues", said David Jenkins, CEO and Executive Chairman of Catheter Precision. "The very initial results of the onboarding of our new sales team, completed with the hire of Marie Claude Jaques as our new Chief Commercial Officer during May, are showing promise. The pipeline of potential customers is established and growing, giving us good insight for future revenue growth."
(0)
(0)
